Physician profile
Arpitha M Reddy
NPI 1740238187
$2,439.37
in general payments reported to CMS, 2019-2025
25 companies · $642 in 2025
The $642 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $225 · 2021: $226 · 2022: $272 · 2023: $306 · 2024: $590 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,535 · Education: $2.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,535.36 |
| Education | $2.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $321.18 | 2019-2024 | Lokelma, Farxiga |
| Amgen INC. | $280.09 | 2019-2025 | Tavneos, Krystexxa, Aranesp |
| Otsuka America Pharmaceutical, INC. | $207.55 | 2019-2025 | Voyxact, Jynarque |
| Novartis Pharmaceuticals Corporation | $177.67 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $150.18 | 2024-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $142.83 | 2021-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $136.15 | 2023-2025 | |
| Lilly USA, LLC | $124.00 | 2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $110.25 | 2021-2025 | Lupkynis |
| Scpharmaceuticals INC. | $104.70 | 2025 | |
| Xeris Pharmaceuticals, INC. | $102.91 | 2022-2024 | Keveyis, Gvoke Hypopen |
| Travere Therapeutics, INC. | $85.00 | 2023-2025 | Filspari |
| Fresenius USA Marketing, INC. | $80.27 | 2021-2022 | |
| Glaxosmithkline, LLC. | $72.67 | 2020-2023 | Benlysta |
| Genzyme Corporation | $71.62 | 2019-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $38.81 | 2021-2022 | |
| Vifor Pharma, INC. | $36.50 | 2024-2025 | Veltassa |
| Amag Pharmaceuticals, INC. | $34.94 | 2021-2022 | |
| Akebia Therapeutics INC | $24.51 | 2020 | |
| Daiichi Sankyo INC. | $24.19 | 2019 | |
| Ardelyx, INC. | $24.16 | 2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $23.88 | 2020 | |
| Nxstage Medical, INC. | $23.76 | 2024 | |
| Shire North American Group INC | $21.57 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.98 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arpitha Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.